This page shows the latest Haemato-oncology news and features for those working in and with pharma, biotech and healthcare.
decreasing benefit,” said Catherine Thieblemont, head of the haemato-oncology unit of St-Louis Hospital.
The company has several years to build up its other franchises, which includes its haemato-oncology therapies.
which underscores the need for new treatments for this disease,” said Bernard Escudier, MD, ex-chairman of the genitourinary oncology committee, Institut Gustave Roussy. ... NSCLC). BMS recently announced a $74bn acquisition of Celgene, a move which
Extends presence in haemato-oncology and solid tumours. Immuno-oncology start-up Dragonfly Therapeutics has bagged a $24 million licensing deal from Celgene for two cancer therapeutics based on natural killer ... That differentiates TriNKETs from other
BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech
Bispecifics and antibody drug conjugates will challenge CAR-Ts. The potentially revolutionary nature of CAR-Ts has made them the hottest properties in haemato-oncology in recent years, but a wave ... refractory follicular lymphoma patients," said Israel
More from news
Approximately 2 fully matching, plus 6 partially matching documents found.
485. Array BioPharma / Loxo Oncology. Multi-year licence and collaboration. Drug candidate (preclinical) discovery of small molecule drugs for oncology targets. ... 208. Talon Therapeutics / Spectrum Pharmaceuticals. Acquisition. Haemato-oncology
neurology and haemato-oncology, respectively.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...